MBBS FRCP FRCPath PhD
Associate Professor of Haematology & Consultant Haematologist
- Cancer Research Divisional Lead, Thames Valley & South Midlands
- Myeloma Lead, Thames Valley Cancer Alliance
- Trustee, Myeloma UK Patient Charity
MRC CARP Fellow
Improving outcomes for patients with plasma cell dyscrasias
Karthik Ramasamy is a Consultant Haematologist at Oxford University Hospitals NHS Trust and Associate Professor of Haematology, Radcliffe Department of Medicine, Oxford UK. Dr Ramasamy is the Director of the Oxford Myeloma Translational Research Centre https://oxford-myeloma.org.uk, and a Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Cancer Alliance Group. He is the Divisional Lead for Cancer research for National Institute for Health Research, Clinical Research Network Thames Valley and South Midlands, UK and leads the National Haemonc Oversight Specialty group. He is an Executive member of the UK Myeloma Forum and is an active member of UK Myeloma Research Alliance. Karthik serves on the Myeloma UK Board, a patient charity exclusively dealing with myeloma advocacy and research. Dr Ramasamy with collaborators is developing a national advisory service for Castleman disease. Dr Ramasamy completed his haematology training in London. Following this, he completed three years as a clinical research fellow working on bone marrow microenvironment in myeloma at King’s College London. Dr Ramasamy is a Chief Investigator of myeloma studies and his academic research interests are early diagnosis of myeloma, myeloma renal, bone disease and myeloma drug resistance mechanisms. Karthik has published over 100 papers and authored textbooks/ chapters on myeloma
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Ramasamy K. et al, (2021), Blood Cancer J, 11
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options.
Ramasamy K. et al, (2021), Blood Rev, 49
Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins.
Campbell L. et al, (2021), Clin Biochem, 95, 81 - 83
COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma.
Ramasamy K. et al, (2021), Br J Haematol
The management of Castleman disease.
Lomas OC. et al, (2021), Br J Haematol